Investigational Drug Information for PF-06463922
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug PF-06463922?
PF-06463922 is an investigational drug.
There have been 16 clinical trials for PF-06463922.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 31st 2021.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Lymphoma. The leading clinical trial sponsors are Pfizer, Clinical research technology Srl, and Fondazione Ricerca Traslazionale.
There are twenty-one US patents protecting this investigational drug and two hundred and ninety-eight international patents.
Summary for PF-06463922
| US Patents | 21 |
| International Patents | 298 |
| US Patent Applications | 60 |
| WIPO Patent Applications | 33 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-12-31) |
| Vendors | 53 |
Recent Clinical Trials for PF-06463922
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib | Pfizer | Phase 1 |
| Lorlatinib Continuation Study | Pfizer | Phase 4 |
| PF-07284892 in Participants With Advanced Solid Tumors | Pfizer | Phase 1 |
Clinical Trial Summary for PF-06463922
Top disease conditions for PF-06463922
Top clinical trial sponsors for PF-06463922
US Patents for PF-06463922
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-06463922 | See Plans and Pricing | Substituted macrocycles useful as kinases inhibitors and methods of use thereof | Teligene Ltd. (Suzhou, CN) | See Plans and Pricing |
| PF-06463922 | See Plans and Pricing | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | See Plans and Pricing |
| PF-06463922 | See Plans and Pricing | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) | See Plans and Pricing |
| PF-06463922 | See Plans and Pricing | Treatment of cancer using anti-CD19 Chimeric Antigen Receptor | The Trustees of the University of Pennsylvania (Philadelphia, PA) Novartis AG (Basel, CH) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06463922
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-06463922 | China | CN107207528 | 2034-08-20 | See Plans and Pricing |
| PF-06463922 | European Patent Office | EP3183256 | 2034-08-20 | See Plans and Pricing |
| PF-06463922 | Japan | JP2017525716 | 2034-08-20 | See Plans and Pricing |
| PF-06463922 | Japan | JP6609308 | 2034-08-20 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
